TLR4 and breast carcinoma: TLR4 activation by an alternative ligand paclitaxel significantly increased lymphatics and subsequent node metastasis in breast cancer models [63], in line with the reports demonstrating TLR4 prominent role in M-LECP differentiation [9] and induction of Th2 cytokines [64].